CanSTEP: Effect of cognitive-motor step exergame training on chemotherapy-induced peripheral neuropathy (CIPN) symptoms in cancer survivors

Not Applicable

Conditions: Chemotherapy-induced peripheral neuropathy
Cancer - Any cancer
Neurological - Other neurological disorders

Registration Number: ACTRN12624000865516

Lead Sponsor: Dr Jasmine Menant

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot yet recruiting

Sex: All

Target Recruitment: 178

Inclusion Criteria

aged 18 years and over;
-greater or equal to 6 months and less than 5 years post-completion of neurotoxic chemotherapy treatment for cancer;
-no scheduled further neurotoxic cancer treatment;
-chemotherapy-induced peripheral neuropathy symptoms impacting lower limbs function;
-able to walk 10 metres without the use of a walking aid;
-willing and able to comply with all study requirements, including treatment, timing and nature of required assessments
-have internet access/Wi-Fi and access to a smart device /computer

Exclusion Criteria

-history of primary brain tumours;
-history of metastases (brain or bone) that could affect balance and mobility;
-known history of peripheral neuropathy prior to neurotoxic chemotherapy for cancer;
-neurological disorders including stroke, Parkinson’s disease, multiple sclerosis, and dementia;
-acute psychiatric condition with psychosis;
-severe visual impairment;
-medical condition precluding balance and stepping exercise;
-have insufficient language skills to provide informed consent and fully participate in the program.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Self-reported neuropathy symptoms burden - EORTC QLQ CIPN-20[EORTC QLQ CIPN-20 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy Induced Peripheral Neuropathy-20 items scale). Baseline, 8-week post-baseline assessment, 16-week post-baseline assessment (primary endpoint), 6-month post-baseline follow-up]

Secondary Outcome Measures